What are the potential side effects of targeting CTLA-4?
While targeting CTLA-4 can enhance the immune response against cancer, it can also lead to immune-related adverse events (irAEs). These side effects occur because the inhibition of CTLA-4 can result in an overactive immune system, potentially causing inflammation and damage to normal tissues. Common irAEs include colitis, dermatitis, and hepatitis.
